Circio logoCircio logo

  • About
      • About Circio
      • CEO Statement
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
  • Technology platform
      • Circio AB
      • circVec platform
  • Pipeline
  • Partnering
  • Investors
      • Press releases
      • Events
      • Financial calendar
      • Warrants exercise 2Q 2026
      • Rights Issue Q1 2026
      • Prospectus
      • Reports
      • Presentations
      • Share facts
      • Largest shareholders
      • Dividend policy
      • Analyst coverage
      • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Articles of Association
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Contact
  • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
  • Contacts
    • About
      • About Circio
      • CEO Statement
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
    • circRNA
    • Clinical programs
    • Partnering
      • Partnering
    • Investors
      • Press releases
      • Events
      • Financial calendar
      • Rights Issue 2026
      • Reports
      • Presentations
      • Prospectus
      • Share and trading information
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
      • General Meetings
      • Articles of Association
      • Board of Directors
      • Nomination Committee
      • Committees
      • Management
      • Contact
    • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
    • Contacts
      • Offices
      • Investors & Media
    Press releases - Non-regulatory
    • Press releases - Regulatory
    • All press releases
    2026
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    All subjects
    • Corporate news
    • Other
    All languages
    • English
    • Norwegian
    June 1, 2026
    Press release - Non-regulatory

    Circio and GenAssist jointly announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

    May 28, 2026
    Press release - Non-regulatory

    Circio hosts live webcast today 28 May 2026 at 10:00 am CEST

    May 27, 2026
    Press release - Non-regulatory

    Circio and AaviGen jointly announce research collaboration to advance novel gene therapies for heart diseases

    May 22, 2026
    Press release - Non-regulatory

    Circio invites to a live webcast on 28 May 2026 to summarize the presentations at ASGCT 2026 and provide an overview of the warrants program

    May 21, 2026
    Press release - Non-regulatory

    Circio files EPO patent application covering critical aspects of its circVec platform for enhanced gene and cell therapy

    May 6, 2026
    Press release - Non-regulatory

    Practical information relating to the warrant program

    April 29, 2026
    Press release - Non-regulatory

    Circio announces research collaboration with the Universidad de Santiago de Compostela’s TraffikGene project to advance non-viral circVec delivery

    April 15, 2026
    Press release - Non-regulatory

    Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

    March 26, 2026
    Press release - Non-regulatory

    Circio enters in vivo cell therapy collaboration with United Immunity

    February 6, 2026
    Press release - Non-regulatory

    Circio Holding ASA completes directed issue of NOK 3.6 million

    January 22, 2026
    Press release - Non-regulatory

    Analyst Group publishes initiation report on Circio

    January 7, 2026
    Press release - Non-regulatory

    Circio and The University of Texas Medical Branch jointly announce collaboration to evaluate circVec for the treatment of infectious diseases

    IR contact
    Dr Erik Digman Wiklund
    Dr Erik Digman Wiklund
    CEO
    erik.wiklund@circio.com
    (+47) 41 33 35 36
    Dr Lubor Gaal
    Dr Lubor Gaal
    CFO & Head of BD
    lubor.gaal@circio.com
    (+34) 683 343 811
    Circio logo

    Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

    • About
    • circRNA
    • Clinical programs
    • Partnering
    • Investors
    • Media
    • Contacts

    CONTACT

    Circio Holding ASA
    Email: contact@circio.com

    • Cookies
    • Privacy policy
    • STAY CONNECTED